Brokerages expect Insmed Incorporated (NASDAQ:INSM) to post earnings per share of ($0.62) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Insmed’s earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($0.65). Insmed reported earnings of ($0.59) per share during the same quarter last year, which suggests a negative year over year growth rate of 5.1%. The firm is expected to announce its next earnings results on Thursday, August 3rd.
According to Zacks, analysts expect that Insmed will report full-year earnings of ($2.50) per share for the current year, with EPS estimates ranging from ($2.72) to ($2.25). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.05) per share, with EPS estimates ranging from ($2.73) to ($1.06). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that cover Insmed.
Insmed (NASDAQ:INSM) last released its quarterly earnings data on Wednesday, May 3rd. The biopharmaceutical company reported ($0.60) EPS for the quarter, hitting analysts’ consensus estimates of ($0.60).
INSM has been the topic of a number of recent research reports. Stifel Nicolaus raised their price target on shares of Insmed from $23.00 to $27.00 and gave the company a “buy” rating in a report on Monday, May 1st. Zacks Investment Research upgraded shares of Insmed from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a report on Wednesday, April 26th.
WARNING: This piece was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/05/20/0-62-eps-expected-for-insmed-incorporated-insm-this-quarter-updated.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Trexquant Investment LP acquired a new position in Insmed during the fourth quarter worth $140,000. Princeton Alpha Management LP increased its position in Insmed by 56.0% in the third quarter. Princeton Alpha Management LP now owns 15,713 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 5,638 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Insmed during the fourth quarter worth $242,000. Parametric Portfolio Associates LLC increased its position in Insmed by 39.2% in the first quarter. Parametric Portfolio Associates LLC now owns 14,417 shares of the biopharmaceutical company’s stock worth $252,000 after buying an additional 4,063 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in Insmed by 18.9% in the third quarter. Wells Fargo & Company MN now owns 24,395 shares of the biopharmaceutical company’s stock worth $355,000 after buying an additional 3,882 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.
Shares of Insmed (NASDAQ:INSM) opened at 17.09 on Wednesday. Insmed has a 12-month low of $9.02 and a 12-month high of $19.35. The stock’s 50 day moving average price is $17.39 and its 200-day moving average price is $15.15. The firm’s market capitalization is $1.06 billion.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.